SEC Form 4 · accession 0001209191-15-048553
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Eamonn P Hobbs
Officer — President & CEO · Director
Period of report
May 28, 2015
Accepted (ET)
Jun 1, 2015 · 8:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 28, 2018 | A | 245,532 | $0.00 | A | 445,254 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3,F4 | $2.18 | May 28, 2015 | A | 498,310 | A | — | May 27, 2025 | Common Stock | 498,310 | 498,310 | D |
Explanation of responses
- F1Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
- F2The shares reported here represent the total number of securities beneficially owned following the reported transaction, excluding awards of performance stock units previously reported as 182,724 shares of common stock that remain subject to the achievement of a performance goal pursuant to the terms of the award and thus were removed from the total amount of securities beneficially owned.
- F3Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F4The options vest in equal quarterly installments over three years from the date of grant.